Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAOR.L Regulatory News (AOR)

  • There is currently no data for AOR

Board Changes

13 May 2005 07:00

Aortech International PLC13 May 2005 For Immediate Release 13 May 2005 AorTech International plc ("AorTech" or the "Company") Board Changes AorTech International plc (AIM:AOR), the biomaterials Intellectual Property andMaterial Manufacturing Company today announces changes to its Board as aconsequence of restructuring of the business. Laurie Rostron, Chairman, and Peter Gibson, Non-Executive Director of theCompany have stepped down and Jon Pither has assumed the role of Chairman. TheBoard also announces the appointment of Dr Stuart Rollason as a Non-ExecutiveDirector. The Board is of the view that the family of Elast-Eon(TM) polymer biomaterials isbeing successfully developed to the point where its potential is increasinglybeing recognised as the material of choice for an array of long-term, highfatigue, blood contacting medical device applications. Good progress has also been made with the internal development of highvalue-added platforms for Elast-Eon(TM), particularly with next generation breast implant and heart valve products. It is anticipated that opportunities for these markets will be exploited through licensing opportunities with its partners, or alternative means of investment. Jon Pither, who has considerable experience of managing such opportunities, hasbeen appointed to oversee the development of these initiatives, for the fullexploitation of these technology assets. It is intended that Union Investment Management Ltd (which has a relationshipwith one of the Company's shareholders) will also be engaged to assist the Boardwith this project. Commenting on the restructuring, Jon Pither, Chairman said: "Elast-Eon(TM) has reached a stage where large established companies in thebiomaterials market should find it attractive to commercialise the successfuldevelopment advances that have been achieved." For further information please contact: AorTech International plcFrank Maguire, Chief Executive 07766 543 649/ 00 1801 201 4336 Buchanan Communications 020 7466 5000Ben Willey, Lisa Baderoon, Rebecca Skye Dietrich Visit AorTech's website at: www.aortech.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Sep 20067:03 amRNSAGM Statement
19th Sep 20064:47 pmRNSHolding(s) in Company
15th Sep 20065:09 pmRNSDirector/PDMR Shareholding
13th Sep 20061:32 pmRNSHolding(s) in Company
13th Sep 20061:31 pmRNSHolding(s) in Company
6th Sep 200612:13 pmRNSAnnual Report and Accounts
5th Sep 20067:03 amRNSDirector/PDMR Shareholding
5th Sep 20067:02 amRNSHolding(s) in Company
31st Aug 20067:01 amRNSFinal Results
15th Aug 20067:00 amRNSMedical Advisory Board
7th Aug 20067:02 amRNSFirst human use of ElastEon
1st Aug 20062:20 pmRNSHolding(s) in Company
19th Jul 20067:01 amRNSHolding(s) in Company
30th Jun 200612:20 pmRNSDirector/PDMR Shareholding
23rd Jun 200611:01 amRNSHolding(s) in Company
28th Apr 20063:38 pmRNSConference Presentation
13th Apr 200611:36 amRNSChange of Adviser
6th Apr 20064:06 pmRNSNotification of Interests
20th Mar 20067:01 amRNSSupply and License Agreement
24th Jan 20068:54 amRNSAward of Govt Grant Funding
9th Dec 20057:01 amRNSInterim Results
7th Dec 20057:01 amRNSUpdate of Postal Poll
25th Nov 20057:00 amRNSFDA Approval
17th Nov 20057:01 amRNSAGM Update
15th Nov 20052:25 pmRNSDirectorate Change
27th Oct 20051:06 pmRNSAGM Statement
23rd Sep 20057:01 amRNSFinal Results
1st Aug 20057:01 amRNSSpinal Disc Licence
13th May 20057:00 amRNSBoard Changes
29th Apr 20057:00 amRNSBreast Implants Presentations

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.